Double-check the volume before proceeding
PubMed Maquart, F.X., Pickart, L., Laurent, M., Gillery, P., Monboisse, J.C., & Borel, J.P
It was originally developed by Novo Nordisk and has been the subject of multiple Phase I and Phase II clinical trials, making it one of the better-characterised GHS peptides in terms of safety and pharmacokinetic data
Clarifying the Guidelines and Decoding the Enigma: Strategies for Anesthetic Management of Patients on Glucagon-Like Peptide-1 Receptor Agonists
The manufacturer recommends that patients using oral hormonal contraceptives switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after tirzepatide initiation and for 4 weeks after each dose escalation
If the fever persists beyond 48 hours or worsens, medical review is necessary